doi: 10.1016/S1470-2045(16)30680-5.
Epub 2016 Dec 23.
Onartuzumab ineffective in non-small-cell lung cancer
- PMID: 28017663
- DOI: 10.1016/S1470-2045(16)30680-5
Item in Clipboard
Onartuzumab ineffective in non-small-cell lung cancer
Lancet Oncol.
2017 Feb.
No abstract available
Similar articles
-
Durvalumab boosts progression-free survival in NSCLC.Lancet Oncol. 2018 Jan;19(1):e11. doi: 10.1016/S1470-2045(17)30895-1. Epub 2017 Nov 23. Lancet Oncol. 2018. PMID: 29175147 No abstract available.
-
Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung.J Clin Oncol. 2017 Feb;35(4):412-420. doi: 10.1200/JCO.2016.69.2160. Epub 2016 Dec 12. J Clin Oncol. 2017. PMID: 27937096 Clinical Trial.
-
Onartuzumab in lung cancer: the fall of Icarus?Expert Rev Anticancer Ther. 2015 May;15(5):487-9. doi: 10.1586/14737140.2015.1031219. Epub 2015 Mar 30. Expert Rev Anticancer Ther. 2015. PMID: 25818471
-
Salvage therapy in patients with advanced non-small cell lung cancer.J Thorac Oncol. 2006 Jul;1(6):582-7. J Thorac Oncol. 2006. PMID: 17409922 Review.
-
Emerging profile of cetuximab in non-small cell lung cancer.Lung Cancer. 2010 Jun;68(3):332-7. doi: 10.1016/j.lungcan.2009.07.012. Epub 2009 Sep 26. Lung Cancer. 2010. PMID: 19783064 Review.
Cited by
-
Status of Agents Targeting the HGF/c-Met Axis in Lung Cancer.Cancers (Basel). 2018 Aug 21;10(9):280. doi: 10.3390/cancers10090280. Cancers (Basel). 2018. PMID: 30134579 Free PMC article. Review.
-
Top-level MET gene copy number gain defines a subtype of poorly differentiated pulmonary adenocarcinomas with poor prognosis.Transl Lung Cancer Res. 2020 Jun;9(3):603-616. doi: 10.21037/tlcr-19-339. Transl Lung Cancer Res. 2020. PMID: 32676323 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
